Surrozen, Inc./DE Capital Expenditures Incurred but Not yet Paid
Surrozen, Inc./DE (SRZN) reported Capital Expenditures Incurred but Not yet Paid of $208.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2021-11-15
- 2021-09-30: Capital Expenditures Incurred but Not yet Paid 9 month $208.00K.
- 2020-09-30: Capital Expenditures Incurred but Not yet Paid 1 month $30.00K; Capital Expenditures Incurred but Not yet Paid 9 month $82.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 1 month | Capital Expenditures Incurred but Not yet Paid 9 month |
|---|---|---|
| 2021-09-30 | $208.00K 10-Q · filed 2021-11-15 | |
| 2020-09-30 | $30.00K 10-Q/A · filed 2021-01-05 | $82.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |